Table 1.
Cohort Characteristics (n = 405)
| Characteristic | Value |
|---|---|
| Age at entry, median (IQR), y | 37 (34–41) |
| Age at menopause, median (IQR), y | 49 (47–52) |
| Duration of follow-up, median (IQR), y | 12.3 (7.1–15.2) |
| Race/ethnicity, % | |
| Non-Hispanic white | 20.5 |
| Non-Hispanic black | 57.8 |
| Hispanic | 21.7 |
| FIB-4, median (IQR) | |
| Entry | 1.3 (0.9–1.9) |
| Last available measure | 2.2 (1.4–4.2) |
| Fibrosis of stage 3 or higher by FIB-4, %a | |
| Entry | 5.9 |
| Last available measure | 32.4 |
| APRI, median (IQR) | |
| Entry | 0.55 (0.38–0.92) |
| Last available measure | 0.68 (0.37–1.56) |
| Fibrosis of stage 3 or higher by APRI, %b | |
| Entry | 5.7 |
| Last available measure | 19.8 |
| Heavy alcohol use, % | |
| Entry | 12.5 |
| Last available measure | 6.2 |
| Marijuana use, % | |
| Entry | 27.6 |
| Last available measure | 16.5 |
| CD4 cell count, median (IQR), cells/μL | |
| Entry | 381 (226–567) |
| Last available measure | 311 (108–574) |
| HIV RNA, IU/mL, median (IQR) | |
| Entry | 15000 (1606–67000) |
| Last available measure | 280 (20–45000) |
| Undetectable HIV RNA at last available measure, % | 25.9 |
| ART use during study, % | 88.2 |
| HCV RNA, IU/mL, median (IQR) | |
| Entry | 2.2 million (580 000–4.0 million) |
| Last available measure | 2.4 million (745 000–5.4 million) |
| HCV treatment history (any type), % | 22.9 |
| Direct-acting antiviral HCV treatment, % | 2.0 |
| HCV genotype, %c | |
| 1 | 88.1 |
| 2 | 2.7 |
| 3 | 7.1 |
| Positive hepatitis B surface antigen, % | 2.5 |
| History of diabetes mellitus, % | 27.2 |
| Metabolic syndrome, % | |
| Entry | 0.7 |
| Last available measure | 10.6 |
| HOMA-IR, median (IQR) | |
| Entry | 2.93 (1.60–5.11) |
| Last available measure | 3.31 (1.82–5.71) |
| Fasting glucose ever ≥110 mg/dL, % | 23.0 |
| Fasting triglycerides ever ≥150 mg/dL, % | 43.4 |
| Waist circumference ever >88 cm, % | 58.3 |
| HDL ever <50 mg/dL, % | 53.3 |
| Body mass index, kg/m2, median (IQR) | 25.2 (22.3–28.7) |
| Entry | |
| Last available measure | 24.7 (21.0–29.3) |
| Hormone replacement therapy, % | 17.9 |
Abbreviations: APRI, aspartate aminotransferase platelet ratio index; ART, antiretroviral therapy; FIB-4, fibrosis 4; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model assessment-estimated insulin resistance; IQR, interquartile range.
aDefined as FIB-4 >3.25.
bDefined as APRI >1.5.
cHCV genotype was missing in 30% of the cohort